Enveric Biosciences has presented research highlighting the its lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. EB-003 is a neuropathogenic and non-hallucinogenic N, ...
PITTSBURGH, PA, UNITED STATES, January 14, 2025 /EINPresswire.com/ -- A new year can bring new beginnings! Let this be the year you try something different to treat ...
MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of ...
Hosted on MSN
Neuronetics Announces Expanded Coverage for NeuroStar TMS to Treat Adolescent Depression
MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) revealed a significant development in mental healthcare, announcing that Evernorth Health Services, a subsidiary of The Cigna Group, has expanded its ...
Cigna's Evernorth unit is expanding coverage for Neuronetics' therapy for depression to adolescents. Neuronetics announced that Evernorth will offer coverage for its NeuroStar Transcranial Magnetic ...
Moment of Clarity has released a new resource titled “What to Know About TMS Therapy for PTSD“, now available on their ...
New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sharing patient and provider stories that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback